Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Free Report) has earned a consensus recommendation of “Buy” from the seven analysts that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that have covered the stock in the last year is $24.57.
A number of research firms have issued reports on AVDL. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Avadel Pharmaceuticals in a research note on Wednesday, September 4th. Rodman & Renshaw began coverage on Avadel Pharmaceuticals in a research note on Wednesday, June 12th. They issued a “buy” rating and a $27.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Avadel Pharmaceuticals in a research note on Wednesday, August 28th.
View Our Latest Report on AVDL
Institutional Trading of Avadel Pharmaceuticals
Avadel Pharmaceuticals Trading Down 1.5 %
AVDL stock opened at $13.40 on Wednesday. Avadel Pharmaceuticals has a twelve month low of $9.50 and a twelve month high of $19.09. The company has a market capitalization of $1.29 billion, a P/E ratio of -7.20 and a beta of 1.53. The firm has a 50 day simple moving average of $15.51 and a 200-day simple moving average of $15.94.
Avadel Pharmaceuticals (NASDAQ:AVDL – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. Avadel Pharmaceuticals had a negative net margin of 111.64% and a negative return on equity of 122.64%. The business had revenue of $41.50 million during the quarter, compared to the consensus estimate of $37.47 million. During the same quarter last year, the company earned ($0.70) earnings per share. The business’s quarterly revenue was up 2666.7% compared to the same quarter last year. On average, research analysts predict that Avadel Pharmaceuticals will post -0.5 EPS for the current year.
About Avadel Pharmaceuticals
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
Read More
- Five stocks we like better than Avadel Pharmaceuticals
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Best Stocks Under $10.00
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.